Skip to Content

Pegloticase Side Effects

In Summary

Commonly reported side effects of pegloticase include: infusion related reaction, nausea, urticaria, bruise, and ecchymoses. Other side effects include: anaphylaxis, chest pain, nasopharyngitis, and vomiting. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to pegloticase: intravenous solution

As well as its needed effects, pegloticase may cause unwanted side effects that require medical attention.

If any of the following side effects occur while taking pegloticase, check with your doctor or nurse immediately:

More common:
  • Chest pain or discomfort
  • cough
  • difficult or labored breathing
  • difficulty with swallowing
  • dizziness
  • facial swelling
  • fast heartbeat
  • fever or chills
  • flushing or redness of the skin
  • gout flare
  • headache
  • hives or welts, itching, or skin rash
  • nausea or vomiting
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • redness of the skin
  • tightness in the chest
  • unusual tiredness or weakness
  • unusually warm skin
  • Decreased urine output
  • dilated neck veins
  • extreme fatigue
  • irregular breathing
  • irregular heartbeat
  • swelling of the face, fingers, feet, or lower legs
  • weight gain

Minor Side Effects

Some pegloticase side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:

More common:
  • Bruise
  • contusion
  • difficulty having a bowel movement (stool)
  • large, flat, blue, or purplish patches in the skin
  • muscle aches
  • sore throat
  • stuffy or runny nose
Less common:
  • Vomiting

For Healthcare Professionals

Applies to pegloticase: intravenous solution


The most commonly reported adverse reactions included gout flares, infusion reactions, nausea, contusion or ecchymosis, nasopharyngitis, constipation, chest pain, anaphylaxis, and vomiting.


Common (1% to 10%): Anaphylaxis

The diagnostic criteria for anaphylaxis included skin or mucosal tissue involvement, and either airway compromise, and/or reduced blood pressure with or without associated symptoms, and a temporal relationship with the injection as well as no other identifiable cause. In clinical trials, 6.5% (n=8) patients receiving this drug every 2-weeks and 4.8% (n=6) of patients receiving this drug every 4 weeks experienced anaphylaxis. All patients had been pretreated with oral antihistamine, IV corticosteroid, and/or acetaminophen. There were no instances in placebo patients.


Infusion reactions occurred in 26% of patients receiving this drug every 2-weeks and 41% of patients receiving this drug every 4 weeks. Manifestations have included urticaria, dyspnea, chest discomfort, chest pain, erythema, and pruritus. These symptoms overlap with those that constitute anaphylaxis, but in the individual patient did not satisfy the clinical criteria for anaphylaxis. Infusion reactions are thought to result from the release of various mediators, such as cytokines. They may occur at any time during the course of treatment with approximately 3% occurring with the first infusion and 91% occurring during the time of infusion. Some infusion reactions improved with the slowing of the infusion rate.[Ref]

Very common (10% or more): Infusion reactions (up to 26%)[Ref]


Very common (10% or more): Anti-pegloticase antibodies (up to 92%)[Ref]


An increase in gout flares is frequently observed upon initiation of anti-hyperuricemic therapy due to changing serum uric acid levels resulting from mobilization of urate from tissue deposits. During clinical trials, the frequency of gout flares was 74%, 81%, and 51% for patients receiving 8 mg every 2 weeks, 8 mg every 4 weeks, and placebo, respectively. In the subsequent 3 months, the frequencies were 41%, 57%, and 67%, respectively. Patients were receiving gout flare prophylaxis with colchicine and/or a NSAID.[Ref]

Very common (10% or more): Gout flares (77%)[Ref]


Common (1% to 10%): Chest pain
Frequency not reported: Congestive heart failure exacerbation[Ref]

During clinical trials, 2 cases of congestive heart failure (CHF) exacerbation were reported among patients receiving 8 mg every 2 weeks. During the open-label extension study while patients continued to receive 8 mg every 2 weeks, 4 patients reported CHF exacerbation.[Ref]


Very common (10% or more): Nausea (12%)
Common (1% to 10%): Constipation, vomiting[Ref]


Common (1% to 10%): Nasopharyngitis[Ref]


Contusions were generally not reported on the day of infusion; most were thought to be related to other factors such as concomitant medications relevant to contusion or ecchymosis, type 1 diabetes mellitus.[Ref]

Very common (10% or more): Contusion or ecchymosis (11%)[Ref]


1. "Product Information. Krystexxa (pegloticase)." Savient Pharmaceuticals, East Brunswick, NJ.

It is possible that some side effects of pegloticase may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.